RANCHO CUCAMONGA, Calif., Nov. 28, 2016 -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the 2016 Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 11:00 a.m. Eastern Time in New York, NY.
This presentation will be made available with a live webcast and may be accessed by visiting Amphastar Pharmaceuticals' website at http://ir.amphastar.com/events.cfm. This webcast will be available for 90 days following the presentation.
About Amphastar:
Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company’s finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company’s website at www.amphastar.com.
The Amphastar Pharmaceuticals logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene®, Amphadase® and Cortrosyn®, are the property of Amphastar Pharmaceuticals, Inc.
Forward-Looking Statement:
All statements in this press release referenced above that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding future financial performance, sales and marketing of its products, market size and growth, the timing of FDA filings or approvals, acquisitions and other matters related to its pipeline of product candidates, its share buyback program and other future events. These statements are not historical facts but rather are based on Amphastar’s historical performance and its current expectations, estimates, and projections regarding Amphastar’s business, operations and other similar or related factors. Words such as “may,” “might,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission. You can locate these reports through the Company’s website at http://ir.amphastar.com and on the SEC’s website at www.sec.gov. Amphastar undertakes no obligation to revise or update information in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause the Company’s expectations to change.
Contact: William J. Peters Chief Financial Officer (909) 476-3416


Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 



